How have CUBT shares performed in 2023?

Curative Biotechnology's stock was trading at $0.02 at the beginning of the year. Since then, CUBT shares have decreased by 38.5% and is now trading at $0.0123. View the best growth stocks for 2023 here .

Are investors shorting Curative Biotechnology?

Curative Biotechnology saw a increase in short interest in November. As of November 15th, there was short interest totaling 14,300 shares, an increase of 31.2% from the October 31st total of 10,900 shares. Based on an average daily trading volume, of 820,600 shares, the short-interest ratio is currently 0.0 days. View Curative Biotechnology's Short Interest .

How do I buy shares of Curative Biotechnology?

Shares of CUBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Curative Biotechnology Stock Price, News & Analysis (OTCMKTS:CUBT)

$0.01

0.00 (-3.91%)

(As of 12/5/2023 05:38 PM ET)

Compare

Today's Range: $0.0123
▼
$0.0124
50-Day Range: $0.0090
▼
$0.0143
52-Week Range: $0.01
▼
$0.03

Volume: 12,402 shs
Average Volume: 368,672 shs
Market Capitalization: $7.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings Short Interest

About Curative Biotechnology Stock (OTCMKTS:CUBT)

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

CUBT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CUBT Stock News Headlines

October 31, 2023 | finanznachrichten.de

Curative Biotechnology, Inc.?: Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

August 18, 2023 | thestreet.com

3 Best Biotech Stocks to Add to Your Portfolio

December 6, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

June 6, 2023 | finance.yahoo.com

Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

June 2, 2023 | bizjournals.com

Sacramento Biotech News

May 24, 2023 | finance.yahoo.com

Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

January 5, 2023 | finanznachrichten.de

Curative Biotechnology, Inc.?: Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study

November 12, 2022 | finance.yahoo.com

Curative Biotechnology, Inc. (CUBT)

December 6, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 8, 2022 | seekingalpha.com

Curative Biotechnology refiles for NYSE uplisting, $8M offering

October 20, 2022 | finanznachrichten.de

Curative Biotechnology, Inc.: Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

September 30, 2022 | seekingalpha.com

Curative Biotechnology files for NYSE American uplisting, $8M IPO

September 26, 2022 | benzinga.com

Curative Biotechnology Stock (OTC:CUBT), Short Interest Report

September 22, 2022 | seekingalpha.com

CUBT Curative Biotechnology, Inc.

June 16, 2022 | finance.yahoo.com

Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

May 12, 2022 | finance.yahoo.com

Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors

May 12, 2022 | finance.yahoo.com

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

May 4, 2022 | yahoo.com

Can You Pay a Mortgage With a Credit Card?

May 3, 2022 | finance.yahoo.com

Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration

May 3, 2022 | finance.yahoo.com

Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular Degeneration

March 21, 2022 | seekingalpha.com

Curative signs agreement with NEI to develop age-related eye disease treatment

March 21, 2022 | morningstar.com

Emily Y. Chew, M.D. of the National Eye Institute Assigned Principal Investigator

March 21, 2022 | finance.yahoo.com

Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration

November 24, 2021 | finance.yahoo.com

[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

November 24, 2021 | finance.yahoo.com

CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

October 12, 2021 | finance.yahoo.com

CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO

October 8, 2021 | apnews.com

CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN ...

See More Headlines

Receive CUBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curative Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:CUBT
CUSIP: N/A
CIK: 1400271
Web: curativebiotech.com
Phone: (561) 418-7725
Fax: 866-900-1002
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 628,923,000
Free Float: N/A
Market Cap: $7.74 million
Optionable: Not Optionable
Beta: -16.15

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Paul M. Michael
Executive Chairman & President
I. Richard Garr
Chief Executive Officer & General Counsel
Ron Bordens
Executive VP-Technical Operations & Manufacturing
Barry A. Ginsberg
Vice Chairman & Chief Strategy Officer

Key Competitors

View All Competitors

CUBT Stock Analysis - Frequently Asked Questions

How have CUBT shares performed in 2023?: Curative Biotechnology's stock was trading at $0.02 at the beginning of the year. Since then, CUBT shares have decreased by 38.5% and is now trading at $0.0123.
View the best growth stocks for 2023 here.
Are investors shorting Curative Biotechnology?: Curative Biotechnology saw a increase in short interest in November. As of November 15th, there was short interest totaling 14,300 shares, an increase of 31.2% from the October 31st total of 10,900 shares. Based on an average daily trading volume, of 820,600 shares, the short-interest ratio is currently 0.0 days.
View Curative Biotechnology's Short Interest.
How do I buy shares of Curative Biotechnology?: Shares of CUBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:CUBT) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial